ANTIMULLARIAN HORMONE VARIATION THROUGHOUT THE MENSTRUAL CYCLE

This prospective cross-sectional study is to assess the Anti-Mullerian hormone variation throughout the menstrual cycle in the number of women suffering from subfertility and attending the Basrah Fertility Center at Basrah Mater nity and Children Hospital. This study was conducted at Basrah Maternity and Children Hospital (Basrah city, south of Iraq) during the pe riod from February 2019 to July 2020.The participants had not used combined oral contraceptive (COC) or being pregnant or breastfeeding for at least 2 months before the study cycle; midcycle was identified by subtracting 14 days from the mean cycle length. Fifty participants were included in this study; they were assessed using specially designed questionnaire. From each attendance 3 blood samples were taken for Anti-mullerian measurment, the first at the early follicular phase, the second one at the midcycle, and the third at the mid-luteal phase of the men strual cycle. differences between AMH1 (early follicular phase) and AMH2 (midcycle) (p-value 0.0001) and between AMH2 and AMH3 (mid-luteal phase) (p-value 0.004), whereas there was no statisti cally significant difference between AMH1 and AMH3. In conclusion, there is a significant intracyclic variation in the level of AMH and which tend to be lower at the mid cycle phase. This table shows the variation in the mean level in a with low, normal, and high In a patient with low mean AMH value, the highest value was at the mid-luteal phase, and the was differences these 3 were statistically significant.